Notable Labs, Inc.’s Acquisition of Development and Commercialization Rights to Volasertib

Wiggin and Dana represented Notable Labs, Inc. on the transaction.

Notable Labs, Inc.), a pioneer and developer of predictive precision medicines, has obtained worldwide rights to volasertib from Oncoheroes Biosciences Inc., a Boston-based biotechnology company focused on advancing new therapies for childhood cancer. 

Under terms of the agreement, Notable will have exclusive rights to develop and commercialize volasertib in leukemias, lymphomas and other adult cancer indications. Oncoheroes will retain the license for development and commercialization of volasertib in pediatric indications.

Financial terms of this deal are not disclosed.

Volasertib is a Polo-like kinase 1 (PLK-1) inhibitor with demonstrated activity in acute myeloid leukemia (AML) and other tumor types with significant unmet medical need.

Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify and select volasertib-responsive patients prior to their treatment and fast-track volasertib’s clinical development in this patient population.

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. 

The Wiggin and Dana team included Partners Patti Melick (Picture) and Jonathan Harris, and Associate Madeleine Tavcar.

Involved fees earner: Jonathan Harris – Wiggin & Dana-Nh ; Patti Melick – Wiggin & Dana-Nh ; Madeleine Tavcar – Wiggin & Dana-Nh ;

Law Firms: Wiggin & Dana-Nh ;

Clients: Notable Labs, Inc.;

Author: Sonia Carcano